Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026
Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026
Company Deals

ELI Radiopharma and United Imaging Research Institute Forge Strategic Alliance to Advance Radiopharmaceutical Innovation

Fineline Cube Aug 4, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

Haixi Pharma’s Oral nAMD Drug Candidate HX9428 Receives FDA Clearance for Phase 2 Trials, Offering Alternative to Intravitreal Injections

Fineline Cube Aug 5, 2026
Company Drug

Sanofi Secures European Commission Approval for MenQuadfi Pediatric Indication Extension to Infants from Six Weeks of Age

Fineline Cube Aug 5, 2026
Company Drug

Henlius Biotech Initiates Phase I Trial for HLX60 in Australia

Fineline Cube Dec 15, 2022

Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the first subject dosed in a Phase...

Company Deals

China Meheco to Import and Distribute Pfizer’s Paxlovid in Mainland China

Fineline Cube Dec 15, 2022

China Meheco Group Co., Ltd (SHA: 600056) has announced an agreement with US major Pfizer...

Company Medical Device

Zylox-Tonbridge Receives NMPA Approval for ZYLOX Octoplus Vena Cava Filter

Fineline Cube Dec 15, 2022

China-based nerve and peripheral vascular interventional device developer Zylox-Tonbridge Medical Technology (HKG: 2190) has announced...

Company Deals

Innovent Biologics Collaborates with LG Chem for Tigulixostat in China

Fineline Cube Dec 15, 2022

China-based Innovent Biologics (HKG: 1801) has announced a strategic collaboration and license agreement with South...

Deals Drug

Everest Medicines Achieves Preclinical Milestone for mRNA Rabies Vaccine

Fineline Cube Dec 15, 2022

China-based Everest Medicines (HKG: 1952) has announced that the company has achieved the preclinical proof-of-concept...

Company Deals

Alternative Bio Completes $15M Seed Round to Advance Cancer Therapeutics

Fineline Cube Dec 15, 2022

Singapore-based Alternative Bio Inc. has announced the completion of a seed financing round at USD...

Company Deals

Shanghai Pharmaceuticals Partners with HKSTP for Biomedicine Cultivation Program

Fineline Cube Dec 14, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), Shanghai Biomedical Frontier Industry Innovation Center Co., Ltd, and...

Company Digital Drug

111 Inc. Begins Online Sales of Pfizer’s Paxlovid in China

Fineline Cube Dec 14, 2022

China-based online pharmacy 111 Inc. (NASDAQ: YI) reportedly initiated online retail sales of Pfizer Inc.’s...

Company Deals

Biosion and ImmunoGen Collaborate on Cancer ADCs

Fineline Cube Dec 14, 2022

China-based Biosion Inc. announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the...

Company Deals

Abcam and Wuxi Diagnostics Expand Partnership into Companion Diagnostics

Fineline Cube Dec 14, 2022

UK-headquartered Abcam plc. and China-based Wuxi Diagnostics have expanded their partnership to dive deep into...

Company Deals

Henlius Biotech Partners with Medilink for Global ADC Development

Fineline Cube Dec 14, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic partnership with Suzhou-based Medilink Therapeutics, obtaining...

Company Drug

Ascentage Pharma’s APG-2575 Shows Promising Results in Global Phase II Study

Fineline Cube Dec 14, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) unveiled preliminary data from the global Phase II clinical study...

Company Medical Device

Lifetech Scientific Completes Enrollment for IBS Coronary Stent Phase II Study

Fineline Cube Dec 14, 2022

China-based Lifetech Scientific Corporation (HKG: 1302) announced that all patients have been enrolled in a...

Policy / Regulatory

China’s COVID-19 Vaccination Second Booster Shot Plan Released

Fineline Cube Dec 14, 2022

The National Health Commission website indicates that the COVID-19 Joint Prevention and Control Mechanism of...

Company Drug

ImmuneOnco’s IMM2520 Receives FDA Clinical Trial Approval

Fineline Cube Dec 14, 2022

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced receiving clinical trial approval from the US FDA for...

Company Drug

Jiangsu Recbio’s COVID-19 Vaccine ReCOV Shows Superiority in Phase II Trial

Fineline Cube Dec 14, 2022

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the positive results of...

Company Drug

Treadwell Therapeutics Presents PLK4 Inhibitor Data at ASH Annual Meeting

Fineline Cube Dec 14, 2022

China-based Treadwell Therapeutics presented results of the company’s CFI-400945 program, a first-in-class inhibitor of Polo-like...

Company Medical Device

Cryofocus Biotechnology’s RDN System Gains FDA Breakthrough Therapy Designation

Fineline Cube Dec 14, 2022

Shanghai-based cryoablation treatment specialist Cryofocus Medtech (Shanghai) Co., Ltd’s in-house developed Cryofocus RDN System, a...

Policy / Regulatory

Beijing Releases COVID-19 Infection Drug List to Address Stocking Issues

Fineline Cube Dec 13, 2022

The Beijing Municipal Health Commission formulated and released the “COVID-19 infection drug list” (first edition),...

Company Deals

Cutia Therapeutic Plans IPO on Hong Kong Stock Exchange

Fineline Cube Dec 13, 2022

China-based dermatology specialist Cutia Therapeutic announced plans to make an initial public offering (IPO) to...

Posts pagination

1 … 624 625 626 … 703

Recent updates

  • Haixi Pharma’s Oral nAMD Drug Candidate HX9428 Receives FDA Clearance for Phase 2 Trials, Offering Alternative to Intravitreal Injections
  • Sanofi Secures European Commission Approval for MenQuadfi Pediatric Indication Extension to Infants from Six Weeks of Age
  • Novo Nordisk Reports Q2 2026 Net Sales of DKK 78.5B, Driven by Strong Semaglutide Performance Despite Portfolio Restructuring
  • Alphamab Oncology’s Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review
  • Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year‑Over‑Year
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Haixi Pharma’s Oral nAMD Drug Candidate HX9428 Receives FDA Clearance for Phase 2 Trials, Offering Alternative to Intravitreal Injections

Company Drug

Sanofi Secures European Commission Approval for MenQuadfi Pediatric Indication Extension to Infants from Six Weeks of Age

Company

Novo Nordisk Reports Q2 2026 Net Sales of DKK 78.5B, Driven by Strong Semaglutide Performance Despite Portfolio Restructuring

Company Drug

Alphamab Oncology’s Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.